Invention Grant
- Patent Title: Interferon alpha 2B variants
-
Application No.: US16710574Application Date: 2019-12-11
-
Publication No.: US11319356B2Publication Date: 2022-05-03
- Inventor: Collette Behrens , Anthony Doyle , Adam Clarke , Matthew Pollard , Teresa Domagala
- Applicant: Teva Pharmaceuticals Australia PTY LTD.
- Applicant Address: AU Macquarie Park
- Assignee: Teva Pharmaceuticals Australia PTY LTD.
- Current Assignee: Teva Pharmaceuticals Australia PTY LTD.
- Current Assignee Address: AU Macquarie Park
- Agency: BakerHostetler
- Priority: AU2014904326 20141029
- Main IPC: C07K14/56
- IPC: C07K14/56 ; C07K16/28 ; A61K39/00 ; A61K39/395

Abstract:
The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon α 2b (IFNα2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFNα2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFNα2b.
Information query